Submission of Integrated Annual Report for FY 2025-26

7th August 2026 IOLCP/CGC/2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai- 400 001 Security Symbol: IOLCP Security Code: 524164 Sub.: Submission of Integrated Annual Report for FY 2025-26 Pursuant to Regulation 34 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Integrated Annual Report of the Company for the financial year 2025-26, containing the Notice convening the 39th Annual General Meeting ("AGM"), which is scheduled to be held on Wednesday, 2nd September 2026 at 11:30 a.m. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"). The aforesaid Annual Report, along with the Notice of the AGM, is being sent through electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. The Annual Report is also available on the Company's website at the following link: https://www.iolcp.com/uploads/Annual_Report_2025-26.pdf Kindly take the above on record. Thanking You, Yours faithfully, For IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr Vice President & Company Secretary Integrated Annual Report 2025-26 Guiding Compass Journey Forward IOL Chemicals and Pharmaceuticals Limited The future rarely unfolds along Guiding Compass for Journey a predictable path. Markets Forward embodies this approach. It reflects our shift. Technologies evolve. New commitment to navigating opportunities emerge. Our products support essential change with confidence, YEARS industries. Our manufacturing advancing with purpose and of Legacy capabilities strengthen supply chains. What matters is creating value that endures. Our commitment to excellence helps Built on build trust across markets. having the clarity Trust As new opportunities emerge and fresh milestones Forty years is not just a marker come into view, we remain focused on the path to stay the course ahead, transforming possibilities into progress and of how far we have come. It ambition into lasting achievement. reflects the strong foundations and the confidence Forty years ago, we began we have built over four with a simple ambition: to move ahead. decades, evidenced by our to build capabilities that 14 USFDA Drug Master Files create lasting value. At IOL, our direction is guided by a compass and 21 EDQM Certificates of forged through decades of experience, Over the decades, that ambition has grown Suitability, while opening new resilience and trust. Consistent quality into an integrated business built on Active possibilities for the future. strengthens confidence. Diversification Pharmaceutical Ingredients and specialty expands our horizons. Disciplined execution chemicals, serving pharmaceutical and As India strengthens its pharmaceutical provides stability. Research and innovation industrial markets across the world. Through leadership, we advance API manufacturing unlock new possibilities. Sustainability every phase of growth, we have stayed close through innovation, quality, and regulatory ensures that growth remains responsible to what matters most: quality, reliability, excellence, delivering trusted solutions that improve global healthcare outcomes. and enduring. innovation and responsible operations. Together, these strengths help us navigate complexity, adapt to change and pursue long-term value creation with purpose. IOL CHEMICALS AND PHARMACEUTICALS LIMITED Corporate Overview Statutory Reports Financial Statements Integrated Annual Report 2025-26 Corporate Overview About the Report 04 Our journey 06 About us This Integrated Report provides an includes material financial and non- the expectations of those we interact 08 Product Portfolio overview of the business performance, financial information relevant to its with most closely 10 Chairman’s Message value creation approach and stakeholders. It provides insights OUR STAKEHOLDERS 12 MD’s Message strategic priorities of IOL Chemicals into business performance across and Pharmaceuticals Limited the pharmaceutical and specialty 14 Investment Case (‘IOL’ / ‘Company’) for the financial chemicals segments, operational 16 Our Sustainability initiatives year ended March 31, 2026. While capabilities, governance practices, risk 22 Growth Strategy incorporating disclosures beyond management, sustainability initiatives Customers Service 24 Business Model statutory requirements, the report and the factors influencing value contractors has been prepared in accordance creation. The disclosures are intended 26 Stakeholder Engagement with the principles and guidance of to present a balanced view of the 28 Double Materiality Assessment the International Integrated Reporting Company’s activities, achievements and 30 Risk management framework Council (IIRC). priorities during the reporting period as Employees and Shareholders/ 34 Governance a standalone legal entity. contractual Investors The report is primarily intended for 38 Board of Directors labourers In this year’s shareholders and prospective investors, REPORTING FRAMEWORKS 40 Financial capital offering insights into the Company's The report has been developed in report 44 Human capital operating environment, governance alignment with the principles outlined 50 Natural capital practices, business model, risks, by the International Integrated Suppliers/ Communities opportunities and long-term value 60 Manufactured capital Reporting Council (IIRC) and with Vendors creation. It also serves as a relevant reference to the Global Reporting 66 Intellectual capital source of information for regulators, Initiative (GRI) Standards. 70 Social and Relationship capital customers, employees, suppliers and communities associated with the The Companies Act, 2013 Company's operations. Government Non-governmental Indian Accounting Standards authorities organisation The disclosures are guided by the SEBI-LODR (Listing Obligations Statutory Reports Companies Act, 2013, Indian Accounting and Disclosure Requirements) Standards (Ind AS) and the SEBI Regulations, 2015 RESPONSIBLE STATEMENT 78 Management Discussion and Analysis 89 Directors’ Report (Listing Obligations and Disclosure ASSURANCE As the management team, we 110 Corporate Governance Report Requirements) Regulations, 2015. By recognise our responsibility for combining financial and non-financial The facts and figures presented the accuracy and reliability of the 126 Business Responsibility & Sustainability Report information, the report aims to provide have been reviewed by the Board of disclosures made in this Integrated a holistic view of how IOL creates and Directors and the Management. Intertek Report. We have ensured that the Financial Statements preserves value in the short, medium India Private Limited has performed information is presented in a balanced, and long term. a limited assurance review on the consistent and understandable 158 Standalone sustainability information contained manner. The report covers all relevant SCOPE AND BOUNDARY 215 Consolidated within the Integrated Report. material matters pertaining to our This Integrated Report presents an operations and stakeholders. It also OUR STAKEHOLDERS AND overview of the operational, financial outlines how the organisation is Notice of Annual General Meeting MATERIALITY ASSESSMENT and strategic performance of IOL positioned to respond to potential risks Chemicals and Pharmaceuticals We maintain ongoing engagement while pursuing growth opportunities. 267 Notice Limited. The report is structured in with investors, customers, employees, accordance with the principles of the regulatory authorities and communities FEEDBACK Annexures International Integrated Reporting to understand their areas of interest Your feedback, inquiries and Framework and adopts the six and relevance. Based on stru [Showing first 8,000 characters — download PDF for full document]